Prospekta is a nootropic drug reported to act on the S100 proteins.[1][2][3][4] It was developed by the company Materia Medica and approved in Russia for the treatment of ADHD in 2022.[5] It was also studied for vascular dementia.[6]
References edit
- ^ Zavadenko, N. N. (1 June 2023). "Neurodevelopmental Disorders in Children: Neuroplasticity and the Possibilities of Nootropic Pharmacotherapy". Neurochemical Journal. 17 (2): 202–210. doi:10.1134/S1819712423020228. ISSN 1819-7132. S2CID 259939682.
- ^ Kardash, E. V.; Ertuzun, I. A.; Alekseeva, I. V.; Tarasov, S. A. (1 April 2023). "Efficacy of the Technologically Processed Antibodies to the Brain-Specific S100 Protein in a Rat Model of Hemorrhagic Stroke". Bulletin of Experimental Biology and Medicine. 174 (6): 741–744. doi:10.1007/s10517-023-05783-5. ISSN 1573-8221. PMID 37157047. S2CID 258566805.
- ^ Zavadenko, N. N.; Makushkin, E. V.; Gaynetdinova, D. D.; Kolokolov, O. V.; Malinina, E. V.; Antipenko, E. A.; Sagutdinova, E. Sh; Khaletskaya, O. V.; Dmitriev, A. V.; Maslova, N. N.; Mashin, V. V.; Panteleeva, M. V. (2022). "[Treatment of attention deficit hyperactivity disorder in children: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 122 (11): 62–68. doi:10.17116/jnevro202212211162. ISSN 1997-7298. PMID 36440779. S2CID 254042619.
- ^ Kardash, E. V.; Petrova, N. V.; Khakimova, G. R.; Tarasov, S. A.; Epstein, O. I.; Peyon, G.; Esneault, E. (February 2023). "Nootropic Activity of Prospekta in a Blind Placebo-Controlled Study in a Model of Focal Cerebral Ischemia in Rats". Bulletin of Experimental Biology and Medicine. 174 (4): 435–439. doi:10.1007/s10517-023-05724-2. ISSN 1573-8221. PMID 36892672. S2CID 257957845.
- ^ "В инструкцию к препарату Проспекта добавлена терапия СДВГ у детей старше 7 лет". materiamedica.ru. Retrieved 12 November 2023.
- ^ Tkacheva, O.N.; Mkhitaryan, E.A.; Kolykhalov, I.V.; Belova, A.N.; Kolokolov, O.V.; Zaslavsky, L.G.; Khasanova, N.M.; Akhmadeeva, L.R.; Bogdanov, E.I. (2023). "Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial". Zhurnal Nevrologii I Psikhiatrii Im. S.S. Korsakova. 123 (7): 41–49. doi:10.17116/jnevro202312307141. PMID 37490664. S2CID 260162423.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |